

Value of endoscopic features for diagnosis of *Helicobacter pylori* induced gastritis and their correlation with histologic aspects

Yazbek Amani, Moussawy Sahar, Sweid Amal, Matar Rasha and Khalil Ali*

Department of Medicine, Division of Gastroenterology, Al Zahraa Hospital University Medical Center, Jnah, Beirut, Lebanon

Abstract

Background: *Helicobacter pylori* infection is a major risk factor for a variety of gastric diseases. Although many tests were developed for its diagnosis, unfortunately all of them have their limitations and issues. Recent studies highlighted the usefulness of macroscopic findings during endoscopy in diagnosis of *H. pylori*. However, the results were contradictory and confusing.

Objectives: Thus, we conducted this study to determine the value of endoscopy in this regard, and to define a correlation between endoscopic findings and histologic findings.

Methods: We started a prospective study on 200 endoscopies done for adult patients in Al- Zahraa Hospital University Medical Center (ZHUMC) beginning from January 1st, 2018 to June 30th, 2018. Patients included are those undergoing diagnostic EGD for dyspeptia. Patients having previous history of *H. pylori* infection or being treated with anti-secretory medications or antibiotics within last four weeks were excluded.

Abnormal endoscopic findings were classified as erythema, edema, erosion (flat/raised); rugal hypertrophy, rugal atrophy, nodularity and mosaic pattern (cobblestone appearance).

Histologic examination was made by one pathologist and results were classified as antral inflammation, mucosal atrophy, intestinal metaplasia and neutrophil activity.

Results: Out of 200 patients, 121 were excluded, and in the 79 remaining, we found that only the mosaic pattern showed high diagnostic yield with a specificity, sensitivity and PPV of 100%.

However, all endoscopic findings failed to predict a specific histomorphological pattern.

Conclusion: We suggest that the mosaic appearance is a reliable indicator for the presence *H. pylori* infection without predicting a specific underlying histological pattern.

Introduction

H.pylori infection is a common chronic bacterial infection residing in the stomach of more than 50% of humans worldwide [1,2]. It is contracted in the early childhood and persists indefinitely unless specific treatment is applied [3,4].

Thousands of researches about *H. pylori*, conducted through 30 years, demonstrated that this bacterium, by its colonization of the human stomach, induces mucosal inflammation and a variety of upper gastrointestinal disorders, such as chronic gastritis, peptic ulcer disease in particular duodenal ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, non-ulcer dyspepsia, gastric cancer and other rare gastric conditions. But its culpability is suspected yet not been approved in other clinical settings, especially non-ulcer (functional) dyspepsia, unexplained iron deficiency anemia, rosacea, coronary artery disease, hepatic encephalopathy, psoriasis, idiopathic thrombocytopenic purpura (ITP) [7,12].

Objectives

As we previously discussed in this work, *Helicobacter pylori* infection appears to be the key risk factor for a variety of gastric lesions

and diseases mainly gastritis, and lately it was classified as carcinogen bacterium because of its proven role in the development of gastric adenocarcinoma.

However, this infection can be cured successfully in 90% of cases with an antibiotic regimen, thereby healing definitely multiple disease states, decreasing their recurrence rate and eliminating the risk for developing one of the most fatal neoplasms.

Therefore, it became an urge need to get a diagnostic tool characterized by a low cost so it can be applied for diagnosis and screening of millions of people worldwide, also it should be simple, reliable, giving reproducible, accurate and rapid results.

***Correspondence to:** Khalil Ali, Department of Medicine, Division of Gastroenterology, Al Zahraa Hospital University Medical Center, Jnah, Beirut, Lebanon, Tel: 009613051039, E-mail: drakhalil29@gmail.com

Key words: histomorphological pattern, *H. pylori*, gastric diseases, duodenal ulcer, gastric mucosa

Received: November 09, 2020; **Accepted:** November 23, 2020; **Published:** November 26, 2020

Although many tests were developed for this purpose and were been continuously improving in the last decades, unfortunately all of them have their limitations and issues.

Recent studies highlighted that some macroscopic findings noted during EGD were highly related to some histomorphological changes and were highly suggestive of the presence of *H.pylori* infection but unfortunately their results were confusing and non conclusive.

In our study, we try to determine the value of endoscopic macroscopic diagnosis of *H. pylori* infection, so if the endoscopists could determine the infection state of his patient on the field, the patient can be discharged immediately from the endoscopy section with the accurate treatment, thereby decreasing time and money wasting, improving management and rendering the situation easier for the physician.

Another objective of our study is to determine an association, if such one is present, between macroscopic findings on EGD and histomorphological findings on biopsy.

Material and methods

Subjects

A total of 200 endoscopies done for adult patients in ZHUMC beginning from January 1st, 2018 to June 30th, 2018 were interpreted prospectively. The cases were randomly chosen (inpatient or outpatient, from both sexes, no specific socioeconomic status and no specific region in lebanon) on the basis of the only inclusion criteria: undergoing a diagnostic EGD for dyspepsia. A patient suffers from dyspepsia if he has either epigastric pain, heartburn, nausea, vomiting, flatulence, eructation, fullness after meals, early satiety or abdominal distention, regardless of the severity of these symptoms.

According to our predetermined protocol, every patient having the below criteria was excluded from the study:

The exclusion criteria are:

- Previous history of *H.pylori* infection.
- Antisecretory medication use within last four weeks to the EGD including PPI, Anti-H2 medications or bismuth containing compound.
- Antibiotic (against *H.pylori*) treatment within last four weeks.
- After review of endoscopic results, patients having gastric or duodenal ulcer on EGD, duodenitis or esophagitis were excluded from the study.

Patients with endoscopically normal looking mucosa were not also included in the study because the aim of our study is to determine endoscopic findings related to *H.pylori* induced gastritis.

Endoscopic procedure

Endoscopy was performed after sedation of the patient with 5 mg midazolam and local anesthesia of the oropharynx with 1% xylocaine spray.

A full endoscopic evaluation of the esophagus, stomach and duodenum were performed in all patients by single advanced physician (>5000 endoscopy).

Endoscopic findings were classified according to present criteria as erythema, edema, erosion (flat/raised), rugal hypertrophy, rugal atrophy, nodularity and mosaic pattern (cobblestone appearance).

The most common dyspeptic symptom was epigastric pain, followed by heartburn, fullness after meals, eructation, early satiety, and vomiting.

Diagnosis

H. pylori infection status was evaluated by histology and RUT in all patients.

For this purpose, two biopsies were obtained, one from the corpus, the other from the antrum. Before sending the biopsy specimens for histologic assessment, a piece of biopsy was used to accomplish RUT for diagnosis and confirmation of *H.pylori* infection status.

Histologic examination was made by one pathologist who was blind to the endoscopic findings. The purpose was to detect *H. pylori* infection, determine gastric histomorphological changes induced by the infection, and classify them according to the updated Sydney System as antral inflammation, mucosal atrophy, intestinal metaplasia and neutrophil activity.

Statistical analysis

The results were analysed statistically, to determine the sensitivity, specificity, PPV, NPV and statistical significance (calculated by Chi square test) of macroscopic features in diagnosing *H. pylori* status of infection and to determine any correlation between endoscopic findings and histomorphological findings.

Results

Of a total of 200 cases reviewed retrospectively over the period extending from January 1st, 2018 to June 30st, 2018, 83 patients were excluded from the study because they had one or more of the exclusion criteria described above. Another group of 31 patients was excluded because of missing data in their medical record.

7 patients had normal appearing mucosa on EGD and there were not included in statistical analysis.

Out of the 79 remaining patients, 33 (41.77%) were male and 46 (58.23%) were female with a female to male ratio of 1.4: 1.

The patient's age ranged from 15 years to 88 years with a mean age of 44.84 years (Figure 1).

As shown by the above diagram, the highest percentage of infection was found in the age groups [13-38] and [39-58] in both males and females (15.19% and 16.46% versus 21.52% and 18.99% respectively). On the other hand, extreme age groups [10-19] and [59-69] showed the less percentages of infection in both males and females (0.00% & 0.00% versus 6.33% & 1.27% respectively)

In our study, 29 (36.71%) patients were smokers and 50(63.29%) were nonsmokers; 4 patients (5.06%) were alcohol drinkers versus 75 (94.94%) were not drinkers.

45 patients (56.96%) were diagnosed to have *H. pylori* positive gastritis while 34(33.04%) were *H. pylori* negative gastritis.

Figure 2 summarizes the results described above, dividing the patients in two groups:

H.pylori positive and *H.pylori* negative gastritis; and showing their distribution according to: gender; age class; tobacco smoking and alcohol consumption.




Figure 1. Diagram showing patient's distribution based on gender and age class, and the percentage of each class

		Total	H. Pylori	No H. Pylori
Gender	Female	46 (58.23%)	24 (52.17%)	22 (47.83%)
	Male	33 (41.77%)	21 (63.63%)	12 (36.37%)
Age Class	[10 - 19]	5 (6.33%)	0 (0%)	5 (100%)
	[20 - 39]	29 (21.52%)	17 (58.62%)	12 (41.38%)
	[40 - 59]	28 (35.44%)	18 (64.28%)	10 (35.72%)
	[60 - 79]	16 (20.25%)	10 (62.50%)	6 (37.50%)
	[80 - 99]	1 (1.27%)	0 (0%)	1 (100%)
Habits	Smokers	29 (36.71%)	16 (55.17%)	13 (44.83%)
	No Smokers	50 (63.29%)	29 (58%)	21 (42%)
	Drinkers	4 (5.06%)	3 (75%)	1 (25%)
	No Drinkers	75 (94.94%)	42 (66%)	33 (44%)
Total	79 (100%)	45 (56.96%)	34 (33.04%)	

Figure 2. Distribution of patients according to infection status, gender, age, tobacco, and alcohol consumption

As shown by the above figure 2, *H. pylori* induced gastritis and non-*H. pylori* gastritis have been found in similar percentages in females (52.17% versus 47.83%). In males, gastritis was found mainly due to *H. pylori* (63.63% versus 36.37% in non *H. pylori* gastritis, respectively).

Based on age group criteria, gastritis was also found mainly due to *H. pylori* in [20-38] and [39-58] (58.62% and 64.28% versus 41.38 and 35.72% in non *H. pylori* gastritis, respectively). Whereas in extreme age groups [10-19] and [58-69] no *H. pylori* was found (0%), therefore all gastritis were non *H. pylori* (100%)

In smoker and non-smoker patients, gastritis was found mainly due to *H. pylori* (55.17% and 58% versus 44.83% and 42% in non *H. pylori* gastritis, respectively).

Also, in alcoholic and non-alcoholic patients, gastritis was found mainly due to *H. pylori*, with wide discrepancy compared to non *H. pylori* gastritis (75% and 66% versus 25% and 44%, respectively).

In the *H. pylori* positive gastritis group, the endoscopic and the histologic findings were distributed as following (Figure 3).

- Endoscopic findings: erythema (62%); mixed findings (more than one finding in the same patient) (22%); raised erosion (7%); nodularity (5%); mosaic pattern (2%); flat erosion (2%).

- Histologic findings: Neutrophil activity (73%); mucosal atrophy (16%); intestinal metaplasia (9%); antral inflammation (2%) (Figure 4).
- In the *H. pylori* negative gastritis group, the distribution is as following: (Figure 12)
- Endoscopic findings: erythema (70%); edema (12%); nodularity (9%); flat erosion (3%); raised erosion (3%); mixed findings (3%).
- Histologic findings: Antral inflammation (50%); intestinal metaplasia (32%); mucosal atrophy (18%).
- The diagnostic value (sensitivity; specificity, positive and negative predictive values) of macroscopic findings is shown in table 1.

Subjects with mosaic pattern showed specificity, sensitivity and PPV of 100%, while NPV was only 66%.

In the other hand, patients with raised erosion showed high specificity of 100% while sensitivity was only about 6%. The correlation between endoscopic and histologic findings are shown in table 2. Neutrophil activity is highly associated with mosaic pattern in 93% of cases.

Discussion

In previous studies treating the value of endoscopic diagnosis of *H. pylori* infection, only one test was used for the diagnosis. However accurate diagnosis of this infection is difficult, and one test used could have significant false results; thus, in our study, we combined two tests for this purpose: histology and RUT making the results more accurate and reliable.

In our study, and because no video-based evaluation was performed, we could not observe detailed mucosal patterns and we could not conduct a blind comparison between endoscopic evaluation of mucosa by more endoscopists, which is a limitation of our study.

In the other hand, one of the inconvenient of histologic diagnosis is its intra- and inter-observer variations, and in our study, histologic interpretation was performed by one single pathologist, which is another limitation of the study.

Reviewing some of previous studies, we noted that results have been contradictory. Khakoo et al. [67] evaluated the significance of




Figure 3. Distribution of and Endoscopic and Histologic Findings in *H. pylori* positive patients




Figure 4. Distribution of Endoscopic and Histologic Findings in *H. pylori* negative patients

Table 1. Diagnostic value of endoscopic findings

Endoscopic Finding	Sensitivity	Specificity	PPV	NPV
Mosaic Pattern	100%	100%	100%	66%
Erythema	2%	29%	4%	18%
Mixed Findings	22%	88%	71%	46%
Nodularity	4%	88%	33%	41%
Raised Erosion	6%	100%	100%	44%
Flat Erosion	2%	97%	50%	42%
Edema	0%	97%	0%	42%

Table 2. Correlation between endoscopic and histologic findings

Endoscopic Findings	Histological Findings				Total
	Neutrophil Activity	Antral Inflammation	Intestinal Metaplasia	Mucosal Atrophy	
Mosaic Pattern	26	0	1	1	28
Erythema	0	17	3	5	25
Mixed findings	3	1	5	5	14
Nodularity	1	0	5	0	6
Raised Erosions	2	0	0	1	3
Flat Erosions	1	0	1	0	2
Edema	0	0	0	1	1
Total	33	18	15	13	79

the endoscopic classification of gastritis by the updated Sydney system (USS) criteria and obtained a low diagnostic yield of 41.8%. They concluded the inappropriateness of an endoscopic diagnosis of gastritis. Belair et al. [68], and Redeen et al. [69] also concluded inappropriate value of endoscopy in making the diagnosis.

But a higher diagnostic yield of 79.5% was obtained by Mihara. In fact, their study was conducted in high endemic area. So, the inconsistency in diagnostic yields might be explained by differences in regional disease prevalence.

In the present study, diagnostic yield was relatively high for only one endoscopic feature: the mosaic pattern. Mosaic pattern was the commonest single endoscopic finding (35%) described.

H. pylori was found in 100% of cases, making this finding specific and sensitive with a high statistical significance (p-value <0.001). Also, we found that this pattern was highly linked to the neutrophil activity histologic pattern (92.8%). However, the result was statistically insignificant (p-value 0.2).

The other findings failed to have a statistical significance in the prediction of *H. pylori* infection status, and in the prediction of histomorphological changes, despite that one pattern, the raised erosion pattern had 100% specificity.

Conclusion

As a summary, our study revealed that the diagnostic yield for *H. pylori* infection status was high only for the mosaic appearance pattern, but results were not conclusive for the other patterns. All endoscopic findings failed to predict a specific histomorphological pattern. We suggest that the mosaic appearance on endoscopy is a reliable indicator of the underlying *H. pylori* induced gastritis.

References

1. Pisani P, Parkin DM, Munoz N (1997) Cancer and infection: estimates of the attributable fraction in 1900. *Cancer Epidemiol Biomarkers Prevent* 6: 389-400.
2. Taylor DN, Parsonnet J (1995) The epidemiology and natural history of *Helicobacter pylori* infection. *Infections of the gastrointestinal tract*. Raven Press, New York, USA. 99: 551-564.

3. Rothenbacher D, Bode G, Brenner H (2002) Dynamics of *Helicobacter pylori* infection in early childhood in a high-risk group living in Germany: loss of infection higher than acquisition. *Aliment Pharmacol Ther* 16: 1663-1668. [Crossref]
4. Rowland M, Daly L, Higgins A, Bourke B, Drumm B (2006) Age-specific incidence of *Helicobacter pylori*. *Gastroenterology* 130: 65-72. [Crossref]
5. Bardhan PK (1997) Epidemiological features of infection in developing countries. *Clin Infect Dis* 25: 973-978. [Crossref]
6. Kusters JG, van Vliet AHM, Kuipers EJ (2006) Pathogenesis of *Helicobacter pylori* infection. *Clinical Microbiology Reviews*. (3th edn), University Medical Center, Rotterdam, The Netherlands. 19: 449-490.
7. Lambert JR (1993) The role of *Helicobacter pylori* in nonulcer dyspepsia. A debate for. *Gastroenterol Clin North Am* 22: 141-151. [Crossref]
8. Lazzaroni M, Bargiggia S, Sangaletti O, Maconi G, Boldorini M, et al. (1996) Eradication of *Helicobacter pylori* and long-term outcome of functional dyspepsia. A clinical endoscopic study. *Dig Dis Sci* 41: 1589-1594. [Crossref]
9. Rinaldi V, Zullo A, Diana F, Capocaccia L (1997) *Helicobacter pylori*, hyperammonemia, and hepatic encephalopathy: is there a correlation? *Am J Gastroenterol* 92: 723-724. [Crossref]
10. Kolibasova K, Tothova I, Baumgartner J, Filo V (1996) Eradication of *Helicobacter pylori* as the only successful treatment in rosacea. *Arch Dermatol* 132: 1393. [Crossref]
11. Patel P, Mendall MA, Carrington D, et al. (1995) Association of *Helicobacter pylori* and *Chlamydia pneumoniae* infections S8 Parsonnet with coronary heart disease and cardiovascular risk factors. *BMJ* 311: 711-714.
12. Sullivan PB, Thomas JE, Wight DG, Strachan DP, Leatham E, et al. (1990) *Helicobacter pylori* in Gambian children with chronic diarrhoea and malnutrition. *Arch Dis Child* 65: 189-191. [Crossref]
13. Capella R, Fiocca C, Comaggia M (1999) Autoimmune gastritis. Gastritis. Philadelphia, USA. pp: 79-96
14. Rugge M, Genta RM (2005) Staging and grading of chronic gastritis. *Hum Pathol* 36: 228-233. [Crossref]
15. Makristathis A, Hirschl AM, Lehours PH, Mégraud F (2004) Diagnosis of *Helicobacter pylori* infection. *Helicobacter* 9: 7-14.
16. O’Keefe J, Moran AP (2008) Conventional, Regulatory, and Unconventional T Cells in the Immunologic Response to *Helicobacter pylori*. *Helicobacter* 13: 1-19. [Crossref]
17. Graham DY, Alpert LC, Smith JL, H. H. Yoshimura HH (1988) Iatrogenic *Campylobacter pylori* infection is a cause of epidemic achlorhydria. *Am J Gastroenterol* 83: 974-980. [Crossref]
18. Marshall BJ, Armstrong JA, McGeachie DB, Glancy RJ (1985) Attempt to fulfil Koch’s postulates for pyloric *Campylobacter*. *Med J Austr* 142: 436-439. [Crossref]
19. Morris A, Nicholson G (1987) Ingestion of *Campylobacter pyloridis* causes gastritis and raised fasting gastric pH. *Am J Gastroenterol* 82: 192-199. [Crossref]
20. Sobala GM, Crabtree JE, Dixon MF, Schorah CJ, Taylor JD, et al. (1991) Acute *Helicobacter pylori* infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. *Gut* 32: 1415-1418.
21. Kuipers EJ, Uytterlinde AM, Pena AS, Hazenberg HJ, Bloemena E, et al. (1995) Increase of *Helicobacter pylori*-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. *Am J Gastroenterol* 90: 1401-1406.
22. Veldhuyzen van Zanten SOJ, Dixon MF, Lee A (1999) The gastric transitional zones: neglected links between gastroduodenal pathology and *Helicobacter* ecology. *Gastroenterology* 116: 1217-1229.
23. Labenz J, Gyenes E, Ruhl GS (1993) Is *Helicobacter pylori* gastritis a macroscopic finding? *Dtsch Med Wochenschr* 118: 176-180.
24. Lame L, Cohen H, Sloane R, Marin-Sorensen M, Weinstein WM (1995) Interobserver agreement and predictive value of endoscopic findings for *H. pylori* and gastritis in normal volunteers. *Gastrointest Endosc* 42: 420-423. [Crossref]
25. Kuipers EJ, Uytterlinde AM, Pena AS, Roosendaal R, Pals G, et al. (1995) Long-term sequelae of *Helicobacter pylori* gastritis. *Lancet* 345: 1525-1528.
26. Sakaki N (1995) Endoscopic diagnosis of gastritis in relation to *Helicobacter pylori* infection and subjective symptoms. *J Clin Gastroenterol* 21: S135-S139.
27. Ho YY, Daskalopoulos G (1995) Can you diagnose *Helicobacter pylori* by macroscopic appearance on endoscopy? (Phase I trial) *Gut* 1: 4C38

28. Bah A, Armstrong D, Vouillamoz D, Dorta G, Duroux P, et al. (1995) Endoscopic features of helicobacter pylori gastritis. *Endosc* 27: 593-596. [[Crossref](#)]
29. Tytgat GNJ (1991) The Sydney system: Endoscopic division. Endoscopic appearances in gastritis/duodenitis. *J Gastroenterol Hepatol* 6: 223-224.
30. Czinn SJ, Dahms BB, Jacobs GH, Kaplan B, Rothstein FC (1986) Campylobacter like organism in association with symptomatic gastritis in children. *J Pediatr* 109: 80-83. [[Crossref](#)]
31. Oderda G, Lerro P, Poli E (1998) Childhood nodular gastritis and Campylobacter pylori. *Endosc* 20: 86.
32. Drumm B, Sherman P, Cutz E, Karmali M (1987) Association of Compylobacter pylori on the gastric mucosa with antral gastritis in children. *N Engl J Med* 316: 1557-1561. [[Crossref](#)]
33. Gasbarrini A, Franceschi F (2005) Does H. pylori infection play a role in idiopathic thrombocytopenic purpura and in other autoimmune diseases? *Am J Gastroenterol* 100: 1271-1273. [[Crossref](#)]
34. Jackson S, Beck PL, Pineo GF, Poon MC (2005) Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. *Am J Hematol* 78 :142-150. [[Crossref](#)]
35. Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, et al. (2005) Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura—a randomized controlled trial. *Am J Gastroenterol* 100: 1265-1270. [[Crossref](#)]
36. Laine L, Lewin DN, Naritoku W, Estrada R, Cohen H (1996) Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. *Gastrointest Endosc* 44: 523-526. [[Crossref](#)]
37. Siddique I, Al-Mekhaizeem K, Alateeqi N, Memon A, Hasan F (2008) Diagnosis of Helicobacter pylori: improving the sensitivity of CLOtest by increasing the number of gastric antral biopsies. *J Clin Gastroenterol* 42: 356. [[Crossref](#)]
38. Chey WD, Wong BC (2007) Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 102: 1808. [[Crossref](#)]
39. Dixon MF, Genta RM, Yardley JH, Correa P, et al. (1996) Classification and grading of gastritis. The updated Sydney system. Internationalworkshop on the histopathology of gastritis, Houston 1994. *Am J Surg Pathol* 20: 1161-1181. [[Crossref](#)]
40. El-Zimaity HM (2000) Accurate diagnosis of Helicobacter pylori with biopsy. *Gastroenterol Clin N Am* 29: 863-869. [[Crossref](#)]
41. Talley NJ, Vakil N (2005) Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. *Am J Gastroenterol* 100: 2324-2337.
42. Liu H, Rahman A, Semino-Mora C, Doi SQ, Dubois A (2008) Specific and sensitive detection of H. pylori in biological specimens by real-time RT-PCR and in situ hybridization. *PLoS One* 3: e2689. [[Crossref](#)]
43. Leide-Svegborn S, Stenström K, Olofsson M, Mattsson S, Nilsson LE, et al. (1999) Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. *Eur J Nucl Med* 26: 573. [[Crossref](#)]
44. Howden CW, Hunt RH (1998) Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. *Am J Gastroenterol* 93: 2330.
45. Perez-Perez GI (2000) Accurate diagnosis of Helicobacter pylori. Culture, including transport. *Gastroenterol ClinNAm* 29: 879-884.
46. Gisbert JP, Pajares JM (2004) Reviewarticle: 13 C-urea breath test in the diagnosis of Helicobacter pylori infection- a critical review. *Aliment Pharmacol Ther* 20: 1001-1017.
47. CheyWD (2000) Accurate diagnosis of Helicobacter pylori. 14 C urea breath test. *Gastroenterol Clin N Am* 29: 895-902.
48. Steen T, Berstad K, Meling T, Berstad A (1995) Reproducibility of the 14 C-urea breath test repeated after 1 week. *Am J Gastroenterol* 90: 2103-2105. [[Crossref](#)]
49. Leodolter A, Dominguez-Muñoz JE, von Arnim U, Kahl S, Peitz U, et al. (1999) Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. *Am J Gastroenterol* 94: 2100-2104. [[Crossref](#)]
50. Montalban C, Norman F (2006) Treatment of gastric mucosaassociated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond. *Expert Rev Anticancer Ther* 6: 361-371.
51. Ho B, Marshall BJ (2000) Accurate diagnosis of Helicobacter pylori. Serologic testing. *Gastroenterol Clin N Am* 29: 853-862.
52. Loy CT, Irwig LM, Katelaris PH, Talley NJ (1996) Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. *Am J Gastroenterol* 91: 1138-1144. [[Crossref](#)]
53. Nurgalieva ZZ, Graham DY (2003) Pearls and pitfalls of assessing Helicobacter pylori status. *Dig Liver Dis* 35: 375-377.
54. Hoang TT, Wheeldon TU, Bengtsson C, Phung DC, Sörberg M (2004) Enzyme linked immunosorbent assay for Helicobacter pylori needs adjustment for the population investigated. *J Clin Microbiol* 42: 627-630. [[Crossref](#)]
55. Gisbert JP, Pajares JM (2004) Stool antigen test for the diagnosis of Helicobacter pylori infection: A systematic review. *Helicobacter* 9: 347-368.
56. Gisbert JP, de la Morena F, Abraira V (2006) Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: A systematic review and meta-analysis. *Am J Gastroenterol* 101: 1921-1930.
57. Viana D, Vakil N, Menegatti M, van't Hoff B, Ricci C, et al. (2002) The stool antigen test for detection of Helicobacter pylori after eradication therapy. *Ann Intern Med* 136: 280-287. [[Crossref](#)]
58. Odaka T, Yamaguchi T, Koyama H, Saisho H, Nomura F (2002) Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. *Am J Gastroenterol* 97: 594-599. [[Crossref](#)]
59. Bravo LE, Realpe JL, Campo C, Mera R, Correa P (1999) Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. *Am J Gastroenterol* 94: 2380-2383. [[Crossref](#)]
60. Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo MM, et al. (2001) Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy. *Aliment Pharmacol Ther* 15: 73-79. [[Crossref](#)]
61. Grino P, Pascual S, Such J, Casellas JA, Niveiro M, et al. (2003) Comparison of stool immunoassay with standard methods for detection of Helicobacter pylori infection in patients with uppergastrointestinal bleeding of peptic origin. *Eur J Gastroenterol Hepatol* 15: 525-529. [[Crossref](#)]
62. Peitz U, Leodolter A, Kahl S, Agha-Amiri K, Wex T, et al. (2003) Antigen stool test for assessment of Helicobacter pylori infection in patients with upper gastrointestinal bleeding. *Aliment Pharmacol Ther* 17: 1075-1084. [[Crossref](#)]
63. Van Leerdam ME, Van Der Ende A, ten Kate FJW, Rauws EAJ, Tytgat GNJ (2003) Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding. *Am J Gastroenterol* 98: 798-801. [[Crossref](#)]
64. Lin HJ, Lo WC, Perng CL, Li AFY, Tseng GY, et al. (2004) Helicobacter pylori stool antigen test in patients with bleeding peptic ulcers. *Helicobacter* 9: 663-638. [[Crossref](#)]
65. Vaira D, Malfertheiner P, Mégraud F, Axon AT, Deltenre M, et al. (1999) Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. *Lancet* 354: 30. [[Crossref](#)]
66. Manes G, Balzano A, Iaquinto G, Lombardi G, Balzano A, et al. (2001) Accuracy of stool antigen test in posteradication assessment of Helicobacter pylori infection. *Dig Dis Sci* 46: 2440. [[Crossref](#)]
67. Khakoo SI, Lobo AJ, Shepherd NA, Wilkinson SP (1994) Histological assessment of the Sydney classification of endoscopic gastritis. *Gut* 35: 1172-1175. [[Crossref](#)]
68. Belair PA, Metz DC, Faigel DO, Furth EE (1997) Receiver operator characteristic analysis of endoscopy as a test for gastritis. *Dig Dis Sci* 42: 2227-2233. [[Crossref](#)]
69. Redeen S, Petersson F, Jonsson KA, Borch K (2003) Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. *Endoscopy* 35: 946-950. [[Crossref](#)]